‘Entourage’ effects ofN-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism
The present invention relates to a process for preparing N-(1-alkenyl)carboxamides of the formula I, which comprises reacting a carboxamide of the formula II with an alkyne of the formula III in the presence of a catalyst selected from among carbonyl complexes, halides and oxides of rhenium, manganese, tungsten, molybdenum, chromium and iron.
A METHOD OF TREATING PERIPHERAL INFLAMMATORY DISEASE
申请人:Dublin City University
公开号:EP3095444A1
公开(公告)日:2016-11-23
An active for use in the treatment or inhibition of an inflammatory disease associated with over-activation of Toll-like Receptor 4 (TLR4), Toll-like Receptor 2 (TLR2) and Myeloid differentiating protein 88 (Myd88) adaptor-like protein (Mal) while maintaining a subject's ability to respond normally to a pathogen, in which the active is an oleamide or a derivative thereof.
Effects of synthetic alkamides on Arabidopsis fatty acid amide hydrolase activity and plant development
作者:Lionel Faure、Ronaldo Cavazos、Bibi Rafeiza Khan、Robby A. Petros、Peter Koulen、Elison B. Blancaflor、Kent D. Chapman
DOI:10.1016/j.phytochem.2014.11.011
日期:2015.2
hydrolase (FAAH) has been described as a key contributor to NAE hydrolysis; however, no enzyme has been associated with alkamide degradation in plants. Herein reported is synthesis of 12 compounds structurally similar to a naturallyoccurring alkamide (N-isobutyl-(2E,6Z,8E)decatrienamide or affinin) with different acyl compositions more similar to plant NAEs and various amino alkyl head groups. These "hybrid"
[EN] LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] CONJUGUÉS LIPIDIQUES POUR L'ADMINISTRATION D'AGENTS THÉRAPEUTIQUES
申请人:ARROWHEAD PHARMACEUTICALS INC
公开号:WO2022056273A1
公开(公告)日:2022-03-17
Disclosed herein are compounds according to Formula (I) comprising PK/PD modulators for delivery of oligonucleotide-based agents, e.g., double stranded RNAi agents, to certain cell types, such for example skeletal muscle cells, in vivo. The PK/PD modulators disclosed herein, when conjugated to an oligonucleotide-based therapeutic or diagnostic agent, such as an RNAi agent, can enhance the delivery of the composition to the specified cells being targeted to facilitate the inhibition of gene expression in those cells.
NOVEL 1,3-BENZOXAZOL-2(3H)-ONES AND THEIR USE AS MEDICAMENTS AND COSMETICS
申请人:DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL
公开号:US20150111935A1
公开(公告)日:2015-04-23
The present invention relates to a novel class of 1,3-benzoxazol-2(3H)-ones and their use as a medicament, preferably as a dermatologic agent, and as a cosmetic. These novel compounds are particularly useful in treating and/or preventing inflammation, irritation, itching, pruritus, pain, oedema and/or pro-allergic or allergic conditions in a patient. Usually they are topically applied to the skin or mucosa in the form of a pharmaceutical or cosmetic composition comprising the compound and a pharmaceutically and/or cosmetically acceptable carrier.